To estimate the potential of SIGLEC15 as a cancer therapeutic target, we examined the homology-directed repair (HRD) and loss of heterozygosity (LOH) of SIGLEC15 in multiple cancers, which are strongly associated with sensitivity to platinum-based drugs and poly ADP-ribose polymerase (PARP) inhibitors (Fig. 1A, B). This evidence concerns the gene SIGLEC15 and cancer.